Opinion

Podcast

Emerging Agents in the Treatment of Rheumatic Diseases

In this MEDcast episode, Drs. Soloman, Sharobeem, and Mease discuss newer mechanisms of actions and emerging therapies in rheumatic diseases and tools that are becoming available to rheumatologists to practice precision medicine.

To watch the video series component of this episode, click here.

00:00 Welcome and introductions

01:40 Novel therapeutic agents targeting pathophysiology of rheumatic diseases

06:15 IL-17A, IL-17F inhibitor bimekizumab

07:42 Tyk2 inhibitor deucravacitnib in rheumatology

09:50 IL-17A inhibitor izokibep in psoriatic arthritis

11:10 Outcome measures in rheumatic diseases

16:20 Molecular signature response classifier (MSRC) test

19:40 Biosimilars in rheumatology

24:30 Precision medicine in clinical practice

29:30 Role of advanced practice practitioners in rheumatology

Related Videos
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
© 2024 MJH Life Sciences

All rights reserved.